Madrigal Pharmaceuticals
MDGL
378 hedge funds and large institutions have $12.4B invested in Madrigal Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 130 increasing their positions, 129 reducing their positions, and 63 closing their positions.
96% more call options, than puts
Call options by funds: $397M | Put options by funds: $203M
1% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 129
0.14% less ownership
Funds ownership: 103.78% → 103.63% (-0.14%)
2% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 63
2% less funds holding
Funds holding: 387 → 378 (-9)
9% less capital invested
Capital invested by funds: $13.7B → $12.4B (-$1.28B)
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$207M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$200M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$112M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$77.4M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$62.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$151M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$108M |
| 3 |
Alkeon Capital Management
New York
|
-$76.4M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$56.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$44.9M |
MDGL Hedge Fund Activity: Q1 2026 in Review
378 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2026, worth a combined $12.4B — down 9.3% from $13.7B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of MDGL and 62 opened new positions — a net loss of 1 holder — while 129 trimmed existing stakes and 130 added.
The largest buyer was Janus Henderson Group, adding an estimated $207M. The largest seller was Paulson & Co, cutting an estimated $151M.
- 378 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2026, down from 387 in Q4 2025.
- Funds reported $12.4B of Madrigal Pharmaceuticals stock for Q1 2026, down 9.3% quarter-over-quarter.
- 62 funds opened new Madrigal Pharmaceuticals positions in Q1 2026 and 63 closed out, a net change of -1 holder.
- The largest Madrigal Pharmaceuticals buyer in Q1 2026 was Janus Henderson Group, an estimated $207M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2026 was Paulson & Co, an estimated $151M sold.
Based on aggregated 13F filings for Q1 2026.